Abstract
Objective: To compare the clinical efficacy of methotrexate and tolerance to the drug in patients with rheumatoid arthritis who were switched from intramuscular to oral administration because of a shortage of the intramuscular preparation.
Methods: 143 patients were switched from intramuscular to oral methotrexate. Of these, 47 were switched back to the intramuscular form. A multiple choice questionnaire was sent by mail to evaluate clinical and biological criteria of efficacy and tolerance.
Results: When methotrexate was first switched from intramuscular to oral administration, increased disease activity, exacerbation of morning pain and hand stiffness, duration of morning stiffness, increased joint pain, and increased joint swelling were observed. There was a greater frequency of gastrointestinal symptoms, but without a significant increase in liver abnormalities. When intramuscular methotrexate became available again, 47 of the 143 patients were switched back and were followed for at least three months. On average, disease manifestations were improved and side effects reduced by the switch.
Conclusions: Methotrexate given intramuscularly had improved clinical efficacy with fewer side effects than given orally. Intramuscular methotrexate administration should be considered when rheumatoid arthritis remains active in spite of high dose oral methotrexate.
Full Text
The Full Text of this article is available as a PDF (47.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arthur Valerie, Jubb Ronald, Homer Dawn. A study of parenteral use of methotrexate in rheumatic conditions. J Clin Nurs. 2002 Mar;11(2):256–263. doi: 10.1046/j.1365-2702.2002.00573.x. [DOI] [PubMed] [Google Scholar]
- Bingham S. J., Buch M. H., Lindsay S., Pollard A., White J., Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003 Aug;42(8):1009–1010. doi: 10.1093/rheumatology/keg246. [DOI] [PubMed] [Google Scholar]
- Burbage G., Gupta R., Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis. 2001 Dec;60(12):1156–1156. doi: 10.1136/ard.60.12.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Campbell M. A., Perrier D. G., Dorr R. T., Alberts D. S., Finley P. R. Methotrexate: bioavailability and pharmacokinetics. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):833–838. [PubMed] [Google Scholar]
- Freeman-Narrod M., Gerstley B. J., Engstrom P. F., Bornstein R. S. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer. 1975 Nov;36(5):1619–1624. doi: 10.1002/1097-0142(197511)36:5<1619::aid-cncr2820360514>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
- Furst D. E. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34 (Suppl 2):20–25. [PubMed] [Google Scholar]
- Hamilton R. A., Kremer J. M. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):86–90. doi: 10.1093/rheumatology/36.1.86. [DOI] [PubMed] [Google Scholar]
- Haraoui B., Pelletier J. P., Cloutier J. M., Faure M. P., Martel-Pelletier J. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum. 1991 Feb;34(2):153–163. doi: 10.1002/art.1780340205. [DOI] [PubMed] [Google Scholar]
- Kremer J. M., Lee J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986 Jul;29(7):822–831. doi: 10.1002/art.1780290702. [DOI] [PubMed] [Google Scholar]
- Letendre P. W., DeJong D. J., Miller D. R. The use of methotrexate in rheumatoid arthritis. Drug Intell Clin Pharm. 1985 May;19(5):349–358. doi: 10.1177/106002808501900503. [DOI] [PubMed] [Google Scholar]
- Osman A., Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis. 2001 Apr;60(4):432–432. doi: 10.1136/ard.60.4.432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rozin A., Schapira D., Balbir-Gurman A., Braun-Moscovici Y., Markovits D., Militianu D., Nahir M. A. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis. 2002 Aug;61(8):756–757. doi: 10.1136/ard.61.8.756. [DOI] [PMC free article] [PubMed] [Google Scholar]